Hofseth Biocare ASA (HBC) - Total Assets
Based on the latest financial reports, Hofseth Biocare ASA (HBC) holds total assets worth Nkr391.35 Million NOK (≈ $41.18 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Hofseth Biocare ASA's book value for net asset value and shareholders' equity analysis.
Hofseth Biocare ASA - Total Assets Trend (2010–2024)
This chart illustrates how Hofseth Biocare ASA's total assets have evolved over time, based on quarterly financial data.
Hofseth Biocare ASA - Asset Composition Analysis
Current Asset Composition (December 2024)
Hofseth Biocare ASA's total assets of Nkr391.35 Million consist of 32.8% current assets and 67.2% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 7.5% |
| Accounts Receivable | Nkr21.46 Million | 6.3% |
| Inventory | Nkr55.92 Million | 16.4% |
| Property, Plant & Equipment | Nkr137.98 Million | 40.4% |
| Intangible Assets | Nkr42.43 Million | 12.4% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Hofseth Biocare ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see HBC market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hofseth Biocare ASA's current assets represent 32.8% of total assets in 2024, an increase from 15.4% in 2010.
- Cash Position: Cash and equivalents constituted 7.5% of total assets in 2024, up from 2.7% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, a decrease from 29.0% in 2010.
- Asset Diversification: The largest asset category is property, plant & equipment at 40.4% of total assets.
Hofseth Biocare ASA Competitors by Total Assets
Key competitors of Hofseth Biocare ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
B&G Foods Inc
NYSE:BGS
|
USA | $2.83 Billion |
|
General Mills Inc
NYSE:GIS
|
USA | $32.40 Billion |
|
The a2 Milk Company Ltd
AU:A2M
|
Australia | AU$1.85 Billion |
|
Lotus Health Group Co
SHG:600186
|
China | CN¥3.27 Billion |
|
New Hope Dairy Co Ltd
SHE:002946
|
China | CN¥9.38 Billion |
|
Greencore Group plc
F:GCG
|
Germany | €1.27 Billion |
|
Qianhe Condiment&Food Co Ltd
SHG:603027
|
China | CN¥4.46 Billion |
|
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.
SHG:605016
|
China | CN¥2.58 Billion |
Hofseth Biocare ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.81 | 0.73 | 2.56 |
| Quick Ratio | 0.47 | 0.36 | 1.87 |
| Cash Ratio | 0.30 | 0.14 | 0.00 |
| Working Capital | Nkr-40.89 Million | Nkr-47.18 Million | Nkr165.29 Million |
Hofseth Biocare ASA - Advanced Valuation Insights
This section examines the relationship between Hofseth Biocare ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 676.61 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | -12.5% |
| Total Assets | Nkr341.37 Million |
| Market Capitalization | $55.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hofseth Biocare ASA's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hofseth Biocare ASA's assets decreased by 12.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hofseth Biocare ASA (2010–2024)
The table below shows the annual total assets of Hofseth Biocare ASA from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr341.37 Million ≈ $35.92 Million |
-12.50% |
| 2023-12-31 | Nkr390.12 Million ≈ $41.05 Million |
-5.09% |
| 2022-12-31 | Nkr411.03 Million ≈ $43.25 Million |
-1.19% |
| 2021-12-31 | Nkr415.97 Million ≈ $43.77 Million |
-9.40% |
| 2020-12-31 | Nkr459.13 Million ≈ $48.31 Million |
+56.69% |
| 2019-12-31 | Nkr293.01 Million ≈ $30.83 Million |
+55.90% |
| 2018-12-31 | Nkr187.94 Million ≈ $19.78 Million |
+2.01% |
| 2017-12-31 | Nkr184.24 Million ≈ $19.39 Million |
+15.62% |
| 2016-12-31 | Nkr159.35 Million ≈ $16.77 Million |
-17.58% |
| 2015-12-31 | Nkr193.35 Million ≈ $20.35 Million |
-11.25% |
| 2014-12-31 | Nkr217.87 Million ≈ $22.93 Million |
+6.25% |
| 2013-12-31 | Nkr205.05 Million ≈ $21.58 Million |
+31.75% |
| 2012-12-31 | Nkr155.64 Million ≈ $16.38 Million |
-1.72% |
| 2011-12-31 | Nkr158.37 Million ≈ $16.66 Million |
+67.48% |
| 2010-12-31 | Nkr94.56 Million ≈ $9.95 Million |
-- |
About Hofseth Biocare ASA
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a salmon oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are ca… Read more